[{"arm_notes": "", "treatment_id": null, "treatment_name": "Current interventions as of 09/09/2020: Group A: patients with COVID-19 early symptoms to received mask placebo 500LRU twice a day + standard of care. Group B: patients with COVID-19 early symptoms to received Sulodexide 500 RLU bid + standard of care Group A and B will be randomized by computer software allocation program. For group A participants; general demographic information will be collected and baseline serum levels of d-dimer; C-reactive protein; Creatinine will be taken; a collaborating physician will be followed to the study under physical home or virtual visit (cell; computer; telephone) every 7 days for a period of 21 days as available; making records of any symptomatology referred to by the patient or need to go to the hospital; in case of admission to hospital; information is requested from your treating physician about its evolution until its release; prior authorization by the patient. Previous interventions: Group A: patients with COVID-19 early symptoms to received placebo + conventional treatment; Group B: patients with COVID-19 early symptoms to received Sulodexide 250 RLU bid + conventional treatment Group C: high risk of infection to received sulodexide 250 RLU Group A and B will be randomized by computer software allocation program; group C will be not randomized. Treatment will last 1 month. For group A participants; general demographic information will be collected and baseline levels of D-dimer taken; will receive placebo on the same packaging as your original sulodexide; a collaborating physician will be followed to the study u", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "Current secondary outcome measures as of 09/09/2020:\n1. Serum levels of D dimer, C-reactive protein, and Creatinine measured by a blood test at baseline and 14 days\n2. Incidence of a thromboembolic event confirmed by ultrasound or CT between baseline and 21 days\n3. Incidence of a major bleeding event between baseline and 21 days", "treatment_id": 1245, "treatment_name": "Sulodexide", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Current secondary outcome measures as of 09/09/2020:\n1. Serum levels of D dimer, C-reactive protein, and Creatinine measured by a blood test at baseline and 14 days\n2. Incidence of a thromboembolic event confirmed by ultrasound or CT between baseline and 21 days\n3. Incidence of a major bleeding event between baseline and 21 days", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]